July 28, 2026

Company Name	Otsuka Holdings Co., Ltd.
Name of Representative	Makoto Inoue President and Representative Director, CEO
Code Number	4578, Prime market of the Tokyo Stock Exchange
Contact	Yuji Kogure Director, Investor Relations Department (Phone: +81-3-6361-7411)

Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2026

Otsuka Holdings Co., Ltd. (the "Company") has revised its consolidated financial forecasts for the first half of FY2026 (January 1 - June 30, 2026), previously announced on February 13, 2026.

1. Revision of the consolidated financial forecasts for the first half of FY2026

	Revenue	Business profit	Operating profit	Profit before tax	Profit for the period	Profit attributable to owners of the Company	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A)	1,218,000	173,000	175,000	172,000	131,000	128,000	243.07
Revised forecast (B)	1,332,000	280,000	278,000	285,000	218,000	215,000	407.90
Amount of change (B-A)	114,000	107,000	103,000	113,000	87,000	87,000	
Change (%)	9.4%	61.8%	58.9%	65.7%	66.4%	68.0%	
(Reference) 1H FY2025 Actual	1,180,766	239,221	242,118	226,343	175,863	173,529	326.12

2. Reasons for the revision

Due to the favorable performance of its businesses during the interim consolidated accounting period, the Company has revised upward its consolidated earnings forecast announced on February 13, 2026.

During the interim consolidated accounting period, revenue exceeded the previous forecast primarily due to the later-than-expected entry of generic versions of JYNARQUE in the United States and ABILIFY MAINTENA in Europe, strong performance of VOYXACT, REXULTI, and LONSURF, as well as the positive impact of foreign exchange rates, mainly reflecting the depreciation of the Japanese yen against the U.S. dollar and the euro.

In addition, research and development expenses are expected to be lower than previously anticipated, mainly due to the discontinuation of development for certain indications of ulotaront and differences in the timing of expense recognition for development projects.

As a result, revenue, business profit, operating profit, profit for the period, and profit attributable to owners of the Company are all expected to exceed the previous forecast.

The Company plans to announce the consolidated financial forecast for the full fiscal year ending December 2026 in conjunction with the financial results announcement on July 31, 2026.

Note: The above forecasts are based on information available and assumptions deemed reasonable by the Company at the time of this announcement. Actual operating results may differ from these projections due to various factors.